{{위키데이터 속성 추적}}
{{Infobox drug
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 460023156
| drug_name         = 
| INN               = 
| type              = <!-- empty -->
| image = Cefixime.svg
| width             = 
| alt               = 
| caption           =

<!-- Clinical data -->
| pronounce         = 
| tradename = 슈프락스(Suprax), 그 외<ref name=genericnames/>
| Drugs.com = {{drugs.com|monograph|cefixime}}
| MedlinePlus = a690007
| licence_CA        = <!-- Health Canada may use generic or brand name (generic name preferred) -->
| licence_EU        = <!-- EMA uses INN (or special INN_EMA) -->
| DailyMedID        = Cefixime
| licence_US        = <!-- FDA may use generic or brand name (generic name preferred) -->
| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AU_comment = 
| pregnancy_US      = B
| pregnancy_US_comment =<ref name="Drugs.com pregnancy">{{웹 인용| title=Cefixime (Suprax) Use During Pregnancy | website=Drugs.com | date=29 March 2019 | url=https://www.drugs.com/pregnancy/cefixime.html | access-date=24 December 2019}}</ref>
| pregnancy_category = 
| dependency_liability = 
| addiction_liability = 
| routes_of_administration = [[경구 투여]](캡슐, 분말, 용액)<ref name="Suprax FDA label">{{웹 인용| title=Suprax- cefixime tablet Suprax- cefixime capsule Suprax- cefixime tablet, chewable Suprax- cefixime powder, for suspension | website=DailyMed | date=26 November 2019 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d0fd45bd-7d52-4fa6-a5f7-f46d5651ffa2 | access-date=23 April 2020}}</ref>
| class             = 
| ATCvet            = 
| ATC_prefix = J01
| ATC_suffix = DD08
| ATC_supplemental =

<!-- Legal status -->
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_AU_comment = 
| legal_BR =  <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F-->
| legal_BR_comment = 
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_CA_comment = 
| legal_DE = <!-- Anlage I, II, III or Unscheduled-->
| legal_DE_comment = 
| legal_NZ = <!-- Class A, B, C -->
| legal_NZ_comment = 
| legal_UK = POM
| legal_UK_comment =<ref name="Suprax SmPC">{{웹 인용 | title=Suprax 200 mg Tablets - Summary of Product Characteristics (SmPC) | website=(emc) | date=20 August 2019 | url=https://www.medicines.org.uk/emc/product/5534/smpc | access-date=23 April 2020 | archive-date=2020-09-22 | archive-url=https://web.archive.org/web/20200922195438/https://www.medicines.org.uk/emc/product/5534/smpc | url-status= }}</ref>
| legal_US = Rx-only
| legal_US_comment = 
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV-->
| legal_UN_comment = 
| legal_status = Rx-only

<!-- Pharmacokinetic data -->
| bioavailability = 30~50%<ref name=AHFS2016>{{웹 인용|title=Cefixime|url=https://www.drugs.com/monograph/cefixime.html|publisher=The American Society of Health—System Pharmacists|access-date=8 December 2016|url-status=live|archive-url=https://web.archive.org/web/20161127220806/https://www.drugs.com/monograph/cefixime.html|archive-date=27 November 2016}}</ref>
| protein_bound = 약 60%
| metabolism = 
| metabolites       = 
| onset             = 
| elimination_half-life = 변동폭이 크지만 평균 3~4시간
| duration_of_action = 
| excretion = [[콩팥]], [[담즙]]

<!-- Identifiers -->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 79350-37-1
| CAS_supplemental  = 
| PubChem = 5362065
| IUPHAR_ligand     = 
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00671
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4514923
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = XZ7BG04GJX
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00258
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 472657
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1541
| NIAID_ChemDB      = 
| PDB_ligand        = 
| synonyms          =

<!-- Chemical and physical data -->
| IUPAC_name = (6''R'',7''R'')-7-{[2-(2-Amino-1,3-thiazol-4-yl)-2-(carboxymethoxyimino)acetyl]amino}-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
| C=16 | H=15 | N=5 | O=7 | S=2
| SMILES = O=C2N1/C(=C(/C=C)CS[C@@H]1[C@@H]2NC(=O)C(=N\OCC(=O)O)/c3nc(sc3)N)C(=O)O
| Jmol              = 
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C16H15N5O7S2/c1-2-6-4-29-14-10(13(25)21(14)11(6)15(26)27)19-12(24)9(20-28-3-8(22)23)7-5-30-16(17)18-7/h2,5,10,14H,1,3-4H2,(H2,17,18)(H,19,24)(H,22,23)(H,26,27)/b20-9-/t10-,14-/m1/s1
| StdInChI_comment  = 
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = OKBVVJOGVLARMR-QSWIMTSFSA-N
| density           = 
| density_notes     = 
| melting_point     = 
| melting_high      = 
| melting_notes     = 
| boiling_point     = 
| boiling_notes     = 
| solubility        = 
| sol_units         = 
| specific_rotation = 
}}

'''세픽심'''(cefixime)은 특히 '''슈프락스'''(Suprax)라는 상품명으로 판매되며 여러 세균 감염을 치료하는 데 사용되는 항생제이다.<ref name=AHFS2016/> [[적응증]]이 되는 감염에는 [[중이염]], [[연쇄상구균 인두염]], [[폐렴]], [[요로감염증]], [[임질]], [[라임병]]이 있다.<ref name=AHFS2016/> 임질의 경우 일반적으로 한 번만 투여하면 된다.<ref name=WHO2008>{{서적 인용| title = WHO Model Formulary 2008 | year = 2009 | isbn = 9789241547659 | vauthors = ((World Health Organization)) | veditors = Stuart MC, Kouimtzi M, Hill SR | hdl = 10665/44053 | author-link = World Health Organization | page=107 | publisher = World Health Organization | hdl-access=free }}</ref> 미국에서는 [[세프트리악손]]에 이어서 임질에 사용할 수 있는 2차 치료제이다.<ref name=AHFS2016/> [[경구 투여]]하여 복용한다.<ref name=AHFS2016/>

일반적인 부작용으로는 [[설사]], [[복통]], [[메스꺼움]] 등 위장관계 부작용이 있다.<ref name=AHFS2016/> 심각한 부작용으로는 [[알레르기]] 반응과 [[클로스트리움 디피실리]]에 의한 [[디피실리균 감염증|설사]]가 있다.<ref name=AHFS2016/> 심각한 [[페니실린 알레르기]] 병력이 있는 사람에게는 권장되지 않는다.<ref name=WHO2008/> 임신 중 사용은 비교적 안전한 것으로 여겨진다.<ref name="Drugs.com pregnancy" /> 3세대 [[세팔로스포린]] 계열의 약물이다.<ref name=AHFS2016/> 세균 세포벽을 파괴하는 방식으로 세균을 죽인다.<ref name=AHFS2016 />

세픽심은 1979년에 특허를 받았고 1989년에 미국에서 의료용으로 승인되었다.<ref name=AHFS2016/><ref name=Fis2006>{{서적 인용| vauthors = Fischer J, Ganellin CR |title=Analogue-based Drug Discovery |date=2006 |publisher=John Wiley & Sons |isbn=9783527607495 |page=495 |url=https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA495 }}</ref> [[WHO 필수 의약품 목록]]에 등재되어 있다.<ref name="WHO21st">{{서적 인용| vauthors = ((World Health Organization)) | title = World Health Organization model list of essential medicines: 21st list 2019 | year = 2019 | hdl = 10665/325771 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | id = WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO | hdl-access=free }}</ref> 미국에서는 [[제네릭 의약품]]으로 판매되고 있다.<ref>{{웹 인용| title=Generic Suprax Availability | website=Drugs.com | url=https://www.drugs.com/availability/generic-suprax.html | access-date=23 April 2020}}</ref>

== 각주 ==
{{각주}}

== 외부 링크 ==
* {{웹 인용| url = https://druginfo.nlm.nih.gov/drugportal/rn/79350-37-1 | publisher = U.S. National Library of Medicine| work = Drug Information Portal| title = Cefixime }}

[[분류:세팔로스포린 계열 항생제]]
[[분류:싸이아졸]]
[[분류:세계 보건 기구 필수 의약품]]
[[분류:피부 독소]]
[[분류:비닐 화합물]]